Tuesday, July 14, 2026

AFFF Leads a Firm-Concentrated July 13 Docket

Firm concentration, not a broad-based intake swell, defined the July 13 landscape: Aqueous Film-Forming Foams Products Liability Litigation (2873) produced 37 filings, with Krentsel & Guzman LLP's 14 far exceeding Douglas & London's four and setting the pace for an environmentally focused docket. Drug and platform dockets supplied the next tier, as Depo-Provera Litigation (3140) added 26 filings led by Hochman Law Firm PLLC's seven and Bryant Law Center PSC's five, while Social Media Adolescent Addiction Personal Injury Products Liability Litigation (3047) brought 19 around Weitz & Luxenberg PC's seven and Keller Postman LLC's six. Volume thinned but firm concentration did not: Uber Passenger Sexual Assault Litigation (3084) logged seven filings, with Hochman Law Firm PLLC submitting three and Chaffin Luhana LLP one, while Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (3060) added six under Johnson Law Group's three and DV Injury Law's one. The distribution points to a plaintiff-bar filing cycle still driven by a handful of firms' repeat-volume practices rather than broad cross-docket acceleration. See the full filing feed and firm-level breakdowns here.

Second Circuit Reopens Tylenol Autism Actions

On July 14, 2026, the Second Circuit's July 13 decision returned Acetaminophen ASD-ADHD Products Liability Litigation (3043) to active litigation after a three-judge panel vacated and remanded the dismissal of more than 500 private actions. The panel held that Judge Denise Cote improperly excluded testimony from three plaintiffs' experts while sustaining the exclusion of two others. The ruling did not decide whether prenatal acetaminophen causes autism or ADHD; it restored the expert-admissibility disputes to the Southern District of New York. The immediate contest is thus a renewed Rule 702 expert-evidence fight, not a merits holding on causation.

FDA Presses Formula Supply-Chain Safeguards

On July 13, 2026, FDA sent a supplier-oversight letter to the infant-formula supply chain after two multistate botulism outbreaks associated with powdered formula and a global cereulide contamination event tied to arachidonic acid oil. FDA told manufacturers and supply-chain partners to understand ingredient origins, production, and risks; monitor recalls, outbreak investigations, and import alerts; and act swiftly when supplier concerns arise. Although the action does not set new lead limits or resolve the claims in Baby Food Products Liability Litigation (3101), it places traceability and ingredient-control records at the center of the current regulatory record for infant-food manufacturers. The development gives counsel a contemporaneous agency benchmark for discovery on supplier diligence and contamination-response systems, even as the heavy-metals dispute remains legally distinct.